Deepak Sampath

TL;DR: The re-engineering of navitoclax is reported to create a highly potent, orally bioavailable and BCL-2–selective inhibitor, ABT-199, which inhibits the growth of BCL–dependent tumors in vivo and spares human platelets, indicating that selective pharmacological inhibition of Bcl-2 shows promise for the treatment of B CL-2-dependent hematological cancers.

TL;DR: A mechanism of action for trastuzumab whereby antibody treatment disrupts ligand-independent HER2/HER3 interactions in HER2-amplified cells is described, leading to downregulation of proximal and distal AKT signaling, and correlates with the antiproliferative effects of trastzumab.

TL;DR: BCL-XL–selective inhibitors have the potential to enhance the efficacy of docetaxel in solid tumors and avoid the exacerbation of neutropenia observed with navitoclax, and demonstrate the translational utility of this toolkit of selective BCL-2 family inhibitors.

TL;DR: Observations suggest that tumour‐secreted miRNAs participate in intercellular communication and function as a novel pro‐angiogenic mechanism.

TL;DR: This work represents the first description of small-molecule MCL-1 inhibitors with sufficient potency to induce clear on-target cellular activity, and demonstrates the utility of these molecules as chemical tools for dissecting the basic biology of M CL-1.